When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Generalized anxiety disorder

Última revisão: 27 Nov 2025
Última atualização: 29 May 2024

Resumo

Definição

History and exam

Key diagnostic factors

  • excessive worry for at least 6 months
  • anxiety not confined to another mental health disorder
  • anxiety not due to medication or substance
  • muscle tension
  • sleep disturbance
  • fatigue
  • restlessness
  • irritability
  • poor concentration
Full details

Other diagnostic factors

  • headache
  • sweating
  • dizziness
  • gastrointestinal symptoms
  • muscle aches
  • increased heart rate
  • shortness of breath
  • trembling
  • exaggerated startle response
  • chest pain
Full details

Risk factors

  • family history of anxiety
  • physical or emotional stress
  • history of physical, sexual, or emotional trauma
  • other anxiety disorder
  • chronic physical health condition
  • female sex
Full details

Diagnostic tests

1st tests to order

  • clinical diagnosis
Full details

Tests to consider

  • thyroid function tests
  • urine drug screen
  • 24-hour urine for catecholamines, metanephrines, normetanephrines, and creatinine
  • pulmonary function tests
  • ECG
Full details

Treatment algorithm

ONGOING

anxiety symptoms meeting DSM-5-TR criteria

anxiety symptoms not meeting DSM-5-TR criteria

Contributors

Authors

Philip John Cowen, MD, FRCPsych, FMedSci

Professor of Psychopharmacology

Department of Psychiatry

University of Oxford

Oxford

UK

Divulgaciones

PJC declares that he has no competing interests.

Agradecimientos

Professor Philip John Cowen would like to gratefully acknowledge Dr Christopher Gale, Dr Richard P. Swinson, Dr Elizabeth Hoge, and Dr Phebe Tucker, previous contributors to this topic.

Divulgaciones

CG is an author of the Royal Australian and New Zealand College of Psychiatrists clinical practice guideline on social phobia, panic disorder, and generalized anxiety disorder. Otago University has commercial and research relationships with multiple pharmaceutical companies. He is an author of a number of references cited in this topic. RPS has personally received royalties for articles published in UpToDate (Wolters Kluwer) and the Compendium of Therapeutic Choices, 2nd edition (Canadian Pharmacists Association). EH is an author of a number of references cited in this topic. PT has conducted research for GlaxoSmithKline, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Astra-Zeneca, Cephalon, Inc., and Ortho-McNeil. She has also consulted for Forest Pharmaceuticals and received honoraria from Pfizer, Inc. and Forest Pharmaceuticals.

Revisores por pares

Lori Davis, MD

Research Director

University of Alabama

School of Medicine Tuscaloosa Campus

College of Community Health Sciences

Tuscaloosa

AL

Divulgaciones

LD declares that she has no competing interests.

Arianna Di Florio, MD, PhD

Senior Clinical Lecturer

Division of Psychological Medicine and Clinical Neurosciences

Cardiff University

United Kingdom

Divulgaciones

ADF declares that she has no competing interests.

Elaine Lockhart, MB, BCH, BAO

Consultant in Paediatric Liaison Psychiatry

Royal Hospital for Children

Glasgow

United Kingdom

Divulgaciones

EL declares that she has no competing interests.

Agradecimiento de los revisores por pares

Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.

Divulgaciones

Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84. Resumen

Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018 Jun;212(6):333-8.Texto completo  Resumen

Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Diferenciales

    • Panic disorder
    • Social anxiety disorder
    • Obsessive-compulsive disorder
    Más Diferenciales
  • Guidelines

    • Screening and diagnosis of mental health conditions during pregnancy and postpartum
    • Treatment and management of mental health conditions during pregnancy and postpartum
    Más Guidelines
  • Patient information

    Anxiety: what is it?

    Anxiety: what are the treatment options?

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal